In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Pace of Development of Molecular Imaging Agents

Executive Summary

The adoption of new in vivo molecular imaging agents may eventually follow the current path of in vitro diagnostics, which for some products is shifting from a cost-effectiveness standard for reimbursement toward an evidence-based. But the companies most likely to support the clinical trials that would establish such benefits are only slowly integrating the development of molecular agents into their core businesses. IVD - an area of acquisition interest for these companies -may be the force that transforms them into more biologically minded and innovation-driven entities, and in so doing it may bolster the development of molecular imaging agents.
Advertisement

Related Content

Another Call for Better Risk Stratification in Cardiac Imaging
Amersham Little Help to GE Healthcare in This Down Market
Siemens--Stealing GE's Thunder
What's Next for Abbott in IVD?
GE Grabs the Spotlight in IVD
Amersham's Push for High-Value Diagnostics
Preparing Molecular Imaging's Future
Imaging in its Heyday: Clinical Applications (Part II)
Imaging in its Heyday: Research Applications (Part 1)
Applying the GE Mantra to Medical Systems

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel